Expertise in
4
conditions

Dr. Reem H. Ghalib

Internal Medicine
Baptist Health Boca Raton Regional Hospital
800 Meadows Rd, 
Boca Raton, FL 
Expertise in
4
conditions
Baptist Health Boca Raton Regional Hospital
800 Meadows Rd, 
Boca Raton, FL 

Overview

Reem Ghalib is a primary care provider, practicing in Internal Medicine in Boca Raton, Florida.

Dr. Ghalib is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Nonalcoholic Steatohepatitis (NASH), Hepatitis C, Non-Alcoholic Fatty Liver Disease, and Hepatitis.

She is actively involved in clinical research, co-authoring 22 peer reviewed articles and participating in 9 clinical trials.

Specialties

Internal Medicine

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Baptist Health Boca Raton Regional Hospital
800 Meadows Rd, Boca Raton, FL 33486

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Enrollment Status: Completed
Publish Date: August 19, 2026
Intervention Type: Drug
Study Drug: HM15211
Study Phase: Phase 2
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Terminated
Publish Date: June 30, 2026
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)
A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: January 05, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
View 8 Less Clinical Trials

22 Total Publications

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
Journal: The American journal of gastroenterology
Published: September 25, 2020
Similar Doctors
Expertise in
28
conditions
Dr. Barry L. Davis
Internal Medicine
Expertise in
28
conditions
Dr. Barry L. Davis
Internal Medicine

Office

1601 Clint Moore Rd Ste 100, 
Boca Raton, FL 
 (4.0 miles away)
561-939-0200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Barry Davis is a primary care provider, practicing in Internal Medicine in Boca Raton, Florida. Dr. Davis is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Bronchiectasis, Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), and Pneumonia. Dr. Davis is currently accepting new patients.

Expertise in
63
conditions
Dr. James H. Chong
Internal Medicine
Expertise in
63
conditions
Dr. James H. Chong
Internal Medicine

Office

4675 Linton Blvd Ste 202, 
Delray Beach, FL 
 (6.7 miles away)
561-495-5700
Languages Spoken:
English, Korean
See accepted insurances
Accepting New Patients
Offers Telehealth

James Chong is a primary care provider, practicing in Internal Medicine in Delray Beach, Florida. Dr. Chong is highly rated in 63 conditions, according to our data. His clinical expertise encompasses Angiodysplasia of the Colon, Barrett Esophagus, Gastroesophageal Reflux Disease (GERD), Endoscopy, and Colonoscopy. Dr. Chong is currently accepting new patients.

Expertise in
77
conditions
Dr. Mohamed Erritouni
Internal Medicine
Expertise in
77
conditions
Dr. Mohamed Erritouni
Internal Medicine

Office

5130 Linton Blvd Ste G6, 
Delray Beach, FL 
 (5.7 miles away)
561-501-4266
Languages Spoken:
English, Arabic, Creoles And Pidgins, French
See accepted insurances
Accepting New Patients

Mohamed Erritouni is a primary care provider, practicing in Internal Medicine in Delray Beach, Florida. Dr. Erritouni is highly rated in 77 conditions, according to our data. His clinical expertise encompasses Atypical Pneumonia, Hospital-Acquired Pneumonia, Lymphangitis, and Pneumonia. Dr. Erritouni is currently accepting new patients.

Frequently Asked Questions about Dr. Reem H. Ghalib

How do I make an appointment with Dr. Reem H. Ghalib?

You can book an appointment with Dr. Reem H. Ghalib by calling their office at 561-955-5362. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Reem H. Ghalib a top-rated expert for Nonalcoholic Steatohepatitis (NASH)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Reem H. Ghalib is classified as an Distinguished expert for Nonalcoholic Steatohepatitis (NASH), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Reem H. Ghalib specialize in?

While Dr. Reem H. Ghalib is a Internal Medicine, they have specific expertise in Nonalcoholic Steatohepatitis (NASH), Hepatitis C, and Non-Alcoholic Fatty Liver Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Reem H. Ghalib participate in research or clinical trials?

Yes. Dr. Reem H. Ghalib has published 22 articles and abstracts on conditions like Nonalcoholic Steatohepatitis (NASH). You can view a list of Dr. Reem H. Ghalib's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Reem H. Ghalib accept my insurance?

Dr. Reem H. Ghalib accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 561-955-5362 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ghalib's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile